<DOC>
	<DOCNO>NCT01887743</DOCNO>
	<brief_summary>The World Health Organization declare childhood obesity `` one serious public health challenge 21st century , '' ( http : //www.who.int/dietphysicalactivity/childhood ) . Given obese child generally exclude clinical trial , little information exist regard impact obesity drug disposition drug action , create gap physician ' knowledge appropriately select dose many critical medication ( e.g. , anticancer agent ) , prevent toxicity associate overdosing , avoid harm under-treatment . The propose study examine effect obesity metabolism commonly used medication , proton pump inhibitor pantoprazole , explore relationship age , obesity , basal metabolic rate genetic control enzyme primarily responsible pantoprazole metabolism . We also validate simple breath test use predict pantoprazole dose requirement obese child . The study design test follow experimental hypothesis : [ 13C ] -pantoprazole pharmacokinetic parameter different non-obese obese child adolescent , collectively ( age group combine ) stratify age group ( SA 1 ) [ 13C ] -pantoprazole pharmacokinetic parameter DOB value ( thus , CYP2C19 activity ) different male female ( SA 1 &amp; 2 ) [ 13C ] -pantoprazole pharmacokinetic parameter DOB ( Delta baseline ) value ( thus , CYP2C19 activity ) independent age age range 6 17 year ( SA 1 &amp; 2 ) Obesity alter relative contribution CYP2C19-dependent non-CYP2C19-dependent ( i.e. , CYP3A4 ) metabolism pantoprazole , measure urinary ratio 4-hydroxy-pantoprazole pantoprazole sulfone ( SA 1 &amp; 2 ) The [ 13C ] -pantoprazole breath test , determine DOB discrete time point ( ) , non-invasive measure CYP2C19 phenotype ( SA 2 ) Clearance pantoprazole ( surrogate CYP2C19 activity ) function REE obese non-obese child adolescent ( SA 3 ) Pantoprazole clearance ( surrogate CYP2C19 activity ) associate fat distribution , determine waist-to-hip ratio ( SA 3 )</brief_summary>
	<brief_title>Pharmacokinetics Pantoprazole CYP2C19 Activity Children Adolescents With GERD : A Pilot Study</brief_title>
	<detailed_description>As pediatric obesity epidemic continue rise , obesity-associated pathologic condition , type II diabetes , hypertension gastroesophageal reflux disease ( GERD ) , become prevalent , , turn , create need good understanding impact obesity drug disposition response pediatric patient obesity . The following proposal design address hypothesis obesity per se significant effect pharmacokinetics CYP2C19 substrates child adolescent . Pantoprazole , proton pump inhibitor ( PPI ) frequently use treatment GERD related condition , ideally suit study , give predominant role CYP2C19 ( Cytochrome P450 subtype 2C19 ) metabolism favorable safety efficacy profile pediatric medicine . The study obesity activity CYP2C19 relevant , previously study pediatrics enzyme catalyzes biotransformation 20 drug frequently use pediatrics ( eg. , PPIs , selective serotonin re-uptake inhibitor ) . Moreover , knowledge CYP2C19 genotype phenotype use individualize drug treatment , make treatment safer effective child . The primary objective propose investigation evaluate effect obesity pharmacokinetics pantoprazole child adolescent . The secondary objective ass utility [ 13C ] -pantoprazole breath test , novel , non-invasive , in-vivo technique , surrogate biomarker CYP2C19 activity pediatric patient . In addition , impact non-genetic variable , rest energy expenditure ( REE ) , CYP2C19 activity investigate . The propose research objectives achieve administration single dose oral [ 13C ] -pantoprazole , safe stable non-radioactive isotope , 100 patient ( male female ) , include 50 obese ( defined BMI &gt; 95th percentile ) 50 non-obese patient , age 6-17 year . Breath sample collect , 8 hour , [ 13C ] -pantoprazole administration quantify 13CO2 ( Carbon 13 dioxide ) /12CO2 ( Carbon 12 dioxide ) infrared spectrometry . Simultaneously , repeat blood sampling use measure pantoprazole , primary CYP2C19 catalyze metabolite . Pantoprazole disposition characterize breath sample plasma level data examine association important covariates ( e.g. , age , hip : waist ratio , BMI , REE , parent drug : metabolite ratio CYP2C19 genotype ) test experimental hypothesis . Data collect analyzed team highly experienced investigator represent field gastroenterology , pediatric clinical pharmacology evolve field obesity medicine .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>Inclusion Criteria Males females 6 17 year age . Pediatric patient primary diagnosis GERD relate symptom , define one following : clinical symptom consistent GERD , diagnosis erosive esophagitis endoscopy , esophageal biopsy histopathology consistent reflux esophagitis , abnormal pH probe study consistent reflux esophagitis , test result consistent GERD . Nonobese : 10th 84th percentile BMI ( 50 subject ) Overweight : great 85th percentile BMI ( 50 subject ) Provide write assent parental permission Exclusion Criteria Inability blood drawn screen lab test Current therapy medication know clinically significantly inhibit induce CYP2C19 , phenytoin , oxcarbazepine , carbamazepine , rifampicin Inability unwillingness fast overnight prior study session Established diagnosis asthma evidence exacerbation &lt; 5 day administration study article . Children asthma well controlled maintenance treatment eligible enrollment study Existence metabolic disease A demonstrate adverse reaction previous pantoprazole PPI exposure Impaired hepatic activity determine routine liver function test define value great equal 3 time agespecific upper limit normal ( ULN ) AST ( aspartate amino transferase ) , ALT ( alanine amino transferase ) , total bilirubin &gt; 2.0 mg/dl , alkaline phosphatase great equal 5 time agespecific ULN Impaired renal function define great equal 3 time agespecific ULN For female , positive urine betahuman chorionic gonadotropin pregnancy test result Any known infection hepatitis B , C , human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>GERD</keyword>
	<keyword>Obesity</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Pantoprazole</keyword>
	<keyword>CYP2C19</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>